Efficacy of Single-Dose Albendazole and Albendazole Plus Ivermectin for Soil-Transmitted Helminth Infection in Children in the Peruvian Amazon

Grei Curico,1 Paul F. Garcia Bardales,1 Tackeshy N. Pinedo Vasquez,1 Wagner Valentino Shapiama Lopez,1 Maribel Paredes Olortegui,1 Francesca Schiaffino,2,3 Pablo Peñataro Yori,3 Josh M. Colston,3 Thomas G. Flynn,3 Graciela Meza Sánchez,4 Hermann Silva Delgado,4 Richard A. Oberhelman,5 and Margaret N. Kosek6*

1Asociación Benéfica PRISMA, Iquitos, Peru; 2Faculty of Veterinary Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru; 3Division of Infectious Disease and International Health, University of Virginia, Charlottesville, Virginia; 4Universidad Nacional de la Amazonia Peruana, Iquitos, Peru; 5Tulane University, New Orleans, Louisiana

Abstract. In countries where soil-transmitted helminth (STH) infections are endemic, deworming programs are recommended to reduce morbidity; however, increasing levels of resistance to benzimidazoles are of concern. In an observational study in Peru, we studied the clinical efficacy of 400 mg of albendazole 20 days after treatment among children aged 2–11 years. Of 426 participants who provided samples, 52.3% were infected with a STH, 144 (33.8%) were positive for Ascaris (41.8% light, 50.8% moderate, and 7.4% heavy infections), 147 (34.5%) were positive for Trichuris (75.2% light, 22.5% moderate, and 2.3% heavy infections), and 1.1% were positive for hookworm species (100% light infections). Additional stool samples were examined at 20, 90, and 130 days after the initial treatment. At 20 days post-administration of albendazole, the cure rate (CR) of Ascaris infection was 80.1% (95% CI: 73.5–86.7), and the egg reduction rate (ERR) was 70.8% (95% CI: 57.8–88.7); the CR for Trichuris infection was 27.1% (95% CI: 20.0–34.3), and the ERR was 29.8% (95% CI: –1.40 to 57.5). Among participants with persistent or recurrent infections with Trichuris, the combined therapy of albendazole (400 mg) and ivermectin at 600 μg/dose increased overall CR for Trichuris infection to 75.2% (95% CI: 67.3–83.2%) with an ERR of 84.2% (95% CI: 61.3–93.8%). Albendazole administration alone for the control of STH was associated with high rates of treatment failure, especially for Trichuris. Combined single doses of albendazole and ivermectin was observed to have improved efficacy.

INTRODUCTION

Soil-transmitted helminth (STH) infections are distributed in tropical and subtropical areas, such as sub-Saharan Africa, the Americas, China, and South Asia, where approximately 1.5 billion people are estimated to be infected.1 More than 267 million preschool children (1–4 years) and 568 million school-age children (5–14 years) living in areas at high risk of transmission are recommended to receive periodic deworming against these infections.2–4

The programmatic administration of anthelmintic drugs recommended by the WHO contributes to a reduction in transmission in STH.5 Deworming by preventive chemotherapy established by WHO and PAHO to eliminate STH morbidity in areas with prevalence >50% is based on a population based treatment (albendazole 400 mg or mebendazole 500 mg) twice a year. In areas with prevalence >20% and <50%, once-yearly treatment is recommended.6,7 In Peru, population-level deworming twice a year in primary health care centers and schools takes place through a program first established in 2017 and reiterated in 2021 guidelines.8 There is, however, growing concern that despite ease of use, the current strategy, which uses a single dose of a single agent, the efficacy of this approach is limited—in particular, in the control of Trichuris infection.9–13

We conducted a prospective observational study designed to evaluate the programmatic efficacy of current STH guidelines. Specifically, we sought to evaluate the clinical response to albendazole monotherapy and time to reinfection of STH among children in the Peruvian Amazon who receive preventive treatment every 6 months according to the Peruvian Ministry of Health guidelines. A secondary aim was to measure the efficacy of combined therapy of albendazole with high-dose ivermectin in the treatment of children who remained persistently infected with Trichuris or other STH after treatment with albendazole monotherapy.

MATERIALS AND METHODS

Study area and design. A prospective cohort study was conducted in the city of Iquitos, Loreto, Peru. Children aged 2–11 years were enrolled, each with an individual duration of participation of 4.5 months with four study visits at specific times between October 2021 and January 2023.

The study was conducted in the jurisdiction of the 6 de Octubre Health Center, which includes riverine, peri-urban, and urban environments. The riparian zone is located on the opposite bank of the Itaya River from the city of Iquitos. It is prone to flooding and lacks basic services, such as electricity and potable water. The peri-urban area is adjacent to the city and extends down to the river, with houses on stilts or houseboats that float on the surface of the river. Many of them have electricity and potable water and are usually close to the health center.

A community census was conducted beforehand to identify eligible children. In the riverine area, all children who met the inclusion criteria were invited to enroll. In the peri-urban and urban area, where there are defined maps with streets and addresses, we recruited a randomized sample of approximately 30% of the eligible target population through approaching every third house and closing blocks clockwise. Demographic data were collected, and children’s weight and height were recorded at the beginning and end of follow-up for each participant. Inclusion criteria included the absence of deworming treatments in the 3 months before enrollment,
as well as permanent residence in the study area with no plans to move over the following 6 months. A detailed study protocol has been published previously.14

History of time since last deworming was obtained. Children had height measured with a commercially available measuring board, and weight was measured to the nearest 10 g with a Tanita scale. The WHO standards were used to express measures as height-for-age Z-scores, weight-for-age Z-scores, and weight for height Z-scores using the 2006 growth standards for children under 60 months of age and the 2007 standard for children 5–11 years of age. Because interpretation of nutritional status is age dependent, the results are presented separately for these different age categories.

Sample processing. A 100-mL sterile plastic vial with a cap was provided to all participants for stool collection 1 day before each visit (first pretreatment sample as well as second, third, and fourth samples on study days 20, 90, and 130 relatives to the day of the first administration of albendazole to measure treatment efficacy and reinfection at 11%, 50%, and 75% of the recommended 6-month interval). These stool samples were analyzed using direct fecal smear and the Kato–Katz technique using a 41.7-mg template.15 All Kato–Katz smears were evaluated independently by two microscopists, and the mean estimate used to enumerate the egg count for each species separately.

Treatment and clinical follow-up. Once the initial stool sample was collected, albendazole 400 mg was administered orally according to the guidelines of the Peruvian Ministry of Health (RM No. 479-2017-MINSA) as part of the universal treatment policy.8 Treatment was directly observed by a study team member. When parasites were found in the samples after the initial treatment, individualized treatment was administered according to current treatment guidelines with preference for effective regimens that were administered in a single dose for programmatic purposes. For Ascaris lumbricoides and hookworm, albendazole 400 mg was administered as a single oral dose. For Trichuris trichiura, both ivermectin 600 μg/kg with albendazole 400 mg were administered together,11,16 and for Strongyloides stercoralis, ivermectin 200 μg/kg/day for 2 days was administered10,17,18 (see Figure 1).

Data management. Data was entered using a double data entry system in an ACCESS database management system (Microsoft, Seattle, WA). Double data entry was performed and differences resolved by a supervisor.

Ethical review. The project was reviewed and approved by the Institutional Ethics Committee of the Asociación Benéfica PRISMA and the Biomedical Institutional Review Board of Tulane University.

STATISTICAL ANALYSES

Definitions. A child was designated as infected with a specified parasite if diagnostic forms were present on either microscopy of direct fecal smears or by Kato–Katz. Infections were categorized as light, moderate, or heavy per WHO guidelines19,20 for each parasite: A. lumbricoides—light (1–4,999 eggs per gram [epg]), moderate (5,000–49,999 epg), and heavy (>50,000 epg); T. trichiura—light 999 epg), moderate (1,000–9,999 epg), and heavy (>10,000 epg); hookworm—light infection (1–1,999 epg), moderate (2,000–3,999 epg), and heavy (>4,000 epg).21

Treatment efficacy was determined through the calculation of cure rates (CRs) and egg rate reduction rates (ERRs). Individuals were considered cured if they converted from positive to negative for a particular STH infection after an
observed treatment was administered. The CRs were calculated by dividing the number of individuals positive at the preintervention survey who were negative at the relevant post-intervention survey by the number of individuals who were positive at the preintervention survey. Changes were evaluated for statistical significance with the Yates $\chi^2$ test. Cure rates were calculated separately and specified as Cure20 (cure after baseline examination and treatment with 400 mg of albendazole as measured at day 20), Cure90 (cure after clinically directed therapy on day 20), and Cure130 (cure after clinically directed therapy on day 90). Cure rates were calculated based on numbers of individuals who supplied stools that enabled cure status to be determined at each treatment cycle. Efficacy of medication in decreasing the intensity of STH was measured for each pathogen after each treatment cycle.

The CR was calculated as follows:

$$\text{CR} (\%) = 100 \times \left( \frac{\# \text{ cured post \text{-} treatment}}{\text{total} \# \text{ of pre \text{-} treatment positives}} \right)$$

The ERR was calculated as follows:

$$\text{ERR} (\%) = 100 \times (1 - \frac{\text{arithmetic mean egg counts at follow \text{-} up}}{\text{arithmetic mean at baseline}}),$$

per WHO norms.22,23 Treatment efficacy of medication was measured separately for each pathogen at each treatment cycle. Confidence intervals were calculated using the bootstrap method with 9,999 iterations. Assessments of treatment efficacy were calculated only for STH with a baseline prevalence that exceeded 10%.

Data analysis was performed in R (version 4.3.1). Sankey diagrams were generated using the networkD3 package (version 0.4).

Reinfections were defined as a reversion to test positivity in an individual who had previously been cured after anthelmintic therapy. Rates of reinfection for each parasite are reported separately for days 90 and 130 and inclusive of all participating individuals who had a stool sample available for analysis at the most distant time point relevant to the period being reported.

RESULTS

Screening and enrollment. One thousand and forty-one children were screened to participate in the study, of whom 600 (57.6%) were excluded (297 children who were dewormed within the previous 3 months, 169 children were under 2 or over 11 years of age, 94 children would be moving within 6 months, 11 children’s parents did not wish to have their child participate, and 29 declined deworming (see Figure 2). Retention in the study was high, with 91.4% (403/441) of enrolled participants providing the first post-treatment stool at day 20, 87.1% (384/441) providing both the first (D20) and second post-treatment stool (D90), and 85% (375/441) of enrollees provided the four specified stool samples during the 4.5-month study period.
Prevalence of infection with STH. The prevalence of *Ascaris* and *Trichuris* infections before albendazole treatment was 33.8% and 34.5%, respectively (Table 2). As the study visits progressed, there was a significant decrease in the prevalence of *Ascaris* infections, with a prevalence of 9.2% in the second visit, 12.2% in the third visit, and 9.6% in the fourth visit. In contrast, for *Trichuris*, the prevalence of infection remained relatively high at 29.3% in the second visit, showing a moderate reduction during subsequent visits with a prevalence of 14.3% in the third visit and 8.5% in the fourth visit after combined albendazole and ivermectin treatment. Hookworm was rare in this population and present in only 0.9%, and *Strongyloides* was identified in 0.5% of pretreatment samples. Coinfections with *Ascaris* and *Trichuris* were common, with 20.7% of participants having a dual infection with these two STH at baseline. Only 52.3% of participants did not have any STH upon pretreatment assessment.

Intensity of infection with STH at baseline. The majority of participants (51.4%) that were positive for *Ascaris lumbricoides* at pretreatment assessment had moderate intensity infections, whereas 41.7% of infections were light and only 6.9% of infections were categorized as heavy at baseline (Table 3). The majority of *Trichuris* infections were light (75.5%) with 22.4% of infections categorized as moderate and only 2.1% of infections as heavy. All hookworm infections documented (4, or 1.1% of baseline samples) were light.

Follow-up and response to standard of care treatment. Follow-up after programmatic treatment with a single dose of albendazole of 400 mg was performed (Supplemental Tables 1 and 2; Figure 3). The CR (C20) for *Ascaris* infections was 80.1% (95% CI: 73.5–86.8), and the ERR was 70.8% (95% CI: 57.8–88.7; Supplemental Table 2; Figure 3A). Before treatment, 6.9% of *Ascaris* infections were heavy, 51.4% were moderate, and 41.7% were light. After albendazole therapy, 10.8% were heavy, 35.1% were moderate, and 53.8% were light. For *Trichuris* infections, the CR at day 20 (C20) was only 27.1% (95% CI: 20.0–34.3) with an ERR of 29.8% (95% CI: −1.40 to 57.5; Supplemental Table 2; Figure 3B). After treatment with albendazole alone, the number of heavy infections decreased from 2.1% to 1.7%, the number of moderate infections decreased from 22.4% to 10.9%, and the number of light infections increased from 75.5% to 87.4%. Treatment responses based on initial infection burden of *Ascaris* and *Trichuris* at the three treatment opportunities (D20, D90, D130) can be seen in Figure 3A and B.

Response to albendazole and ivermectin single-dose combined therapy. Treatment responses in children with *Trichuris* infection who received albendazole and ivermectin resulted in CRs of 75.2% (95% CI: 67.3–83.2%) and ERRs of 84.2% (95% CI: 61.3–93.8%) on the first round on day 90 and a CR of 68.5% (95% CI: 55.6–81.5%) and an ERR of 80.9 (95% CI: 59.3–93.6%) at day 130 (Figure 3B). Both the ERR and CR were approximately 3 times higher with dual therapy compared monotherapy at the both the 90- and 130-day time points (P < 0.01 for both CR and ERR). All heavy *Trichuris* infections were cured or downgraded with dual therapy (Figure 3B).

A group of children that had infection with both *Ascaris* and *Trichuris* infections received this dual therapy, whereas those infected with *Ascaris* only or *Ascaris* and hookworm received albendazole alone. Cure rates for children infected with *Ascaris* infection alone treated on day 90 with albendazole were 83.3% (95% CI: 66.7–100) compared with 75.0% (95% CI: 50.0–93.75) for those treated with both albendazole and ivermectin. Egg reduction rates for *Ascaris* infection among children receiving dual therapy with albendazole and ivermectin were 67.4% (95% CI: 28.0–99.1) compared with...
80.6% (95% CI: 46.6–100) for children with albendazole alone. Neither CRs or reduction in intensity of infection for ascariasis was significantly different between children treated with albendazole alone or albendazole combined with ivermectin at day 90 or 130.

Reinfection. Reinfection with Ascaris occurred at a rate of 18.6% after albendazole-only therapy between days 20 and 90, and 11.8% of those cured at day 90 were reinfected by day 130 after initial therapy (Table 4). Reinfection with Trichuris occurred in 41.2% of 34 children obtaining cure after single-dose albendazole between days 20 and 90 post-treatment. After dual therapy with albendazole and ivermectin, reinfections with Trichuris occurred in 7.1% of the 70 children cured between days 90 and 130 after initial deworming.

DISCUSSION

The burden of STH infection was high in Iquitos, Peru in a community that had excellent access to intervention at the interval specified by the WHO. Five years after programmatic initiation, STH prevalence still approached 50% among children aged 2–11 years, and more than 50% of these infections were of at least moderate intensity. This high prevalence is unexpected because 67.9% of children had been dewormed in the previous 6 months, a number that is nearly equal to the population target of 75% specified by current guidelines that is predicted to diminish both disease burden and transmission. These findings contrast sharply with outcomes reported elsewhere. In Zimbabwe, helminth infections were nearly eliminated with the implementation of the same program in the same manner, albeit in a setting of lower prevalence and intensity. This suggests that in the Peruvian Amazon, and likely in other settings, intensification of anthelmintic treatment and or modification of the treatment used will be needed to attain 2030 goals to diminish the prevalence of moderate to heavy infections to <1%.

Our prospective observational study of single-dose albendazole documented lower CRs and ERRs for both ascariasis and trichuriasis than reference efficacy for albendazole. The WHO lists ERRs of 95% as reference efficacy for Ascaris infections and 50% for Trichuris infection based on the work of Vercruysse, compared with our observed ERR of 70.8% (95% CI: 57.9–88.7) for Ascaris infections and 29.8% (95% CI: 20.0–34.3) for Trichuris infections. The rates of albendazole efficacy are considerably lower than those measured in multiple recent studies and provide empirical evidence of diminished clinical efficacy of albendazole for the treatment of Ascaris infection in the region. Furthermore, Trichuris

### Table 2

Prevalence of helminth infection pretreatment and at three subsequent follow-ups by direct observation

<table>
<thead>
<tr>
<th>STH</th>
<th>Visit 1 (Day 1)</th>
<th>Visit 2 (Day 20)</th>
<th>Visit 3 (Day 90)</th>
<th>Visit 4 (Day 130)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>% (n/N)</td>
<td>% (n/N)</td>
<td>% (n/N)</td>
<td>% (n/N)</td>
</tr>
<tr>
<td>Trichuris trichiura</td>
<td>34.5 (147/426)</td>
<td>29.5 (119/403)</td>
<td>14.3 (55/384)</td>
<td>8.5 (32/375)</td>
</tr>
<tr>
<td>Ascaris lumbricoides</td>
<td>33.8 (144/426)</td>
<td>9.2 (37/403)</td>
<td>12.2 (47/384)</td>
<td>9.6 (36/375)</td>
</tr>
<tr>
<td>Hookworm</td>
<td>0.9 (4/426)</td>
<td>0.5 (2/403)</td>
<td>0.8 (3/384)</td>
<td>0.3 (1/375)</td>
</tr>
<tr>
<td>Strongyloides stercoralis</td>
<td>0.5 (2/426)</td>
<td>0.3 (1/403)</td>
<td>0.7 (1/384)</td>
<td>0.0 (0/375)</td>
</tr>
<tr>
<td>Ascaris/Trichuris coinfection</td>
<td>20.7 (88/426)</td>
<td>4.5 (18/403)</td>
<td>5.2 (20/384)</td>
<td>2.1 (8/375)</td>
</tr>
<tr>
<td>Ascaris lumbricoides only</td>
<td>13.1 (56/426)</td>
<td>4.7 (19/403)</td>
<td>7.0 (27/384)</td>
<td>7.7 (29/375)</td>
</tr>
<tr>
<td>Trichuris trichiura only</td>
<td>13.8 (59/426)</td>
<td>24.8 (100/403)</td>
<td>9.1 (55/384)</td>
<td>6.9 (26/375)</td>
</tr>
<tr>
<td>No STH</td>
<td>52.3 (223/426)</td>
<td>66.0 (266/403)</td>
<td>79.1 (302/382)</td>
<td>84 (315/375)</td>
</tr>
</tbody>
</table>

STH = soil-transmitted helminth.

### Table 3

Intensity of Ascaris lumbricoides, Trichuris trichiura, and Hookworm sp. infection at baseline in enrolled children

<table>
<thead>
<tr>
<th>Intensity of Infection</th>
<th>Visit 1 (Day 1)</th>
<th>Visit 2 (Day 20)</th>
<th>Visit 3 (Day 90)</th>
<th>Visit 4 (Day 130)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>% (n/N)</td>
<td>% (n/N)</td>
<td>% (n/N)</td>
<td>% (n/N)</td>
</tr>
<tr>
<td>Ascaris lumbricoides*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>66.2 (282/426)</td>
<td>90.8 (366/403)</td>
<td>87.8 (337/384)</td>
<td>90.4 (339/375)</td>
</tr>
<tr>
<td>Light</td>
<td>41.7 (60/144)</td>
<td>54.1 (20/37)</td>
<td>63.8 (30/47)</td>
<td>58.3 (21/36)</td>
</tr>
<tr>
<td>Moderate</td>
<td>51.4 (74/144)</td>
<td>35.1 (13/37)</td>
<td>31.9 (15/47)</td>
<td>41.7 (15/36)</td>
</tr>
<tr>
<td>Heavy</td>
<td>6.9 (10/144)</td>
<td>10.8 (4/37)</td>
<td>4.3 (2/47)</td>
<td>0 (0/36)</td>
</tr>
<tr>
<td>Trichuris trichiura*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>65.5 (273/426)</td>
<td>70.5 (284/403)</td>
<td>85.4 (328/384)</td>
<td>91.5 (343/375)</td>
</tr>
<tr>
<td>Light</td>
<td>75.5 (111/147)</td>
<td>87.4 (104/119)</td>
<td>89.3 (50/56)</td>
<td>93.8 (30/32)</td>
</tr>
<tr>
<td>Moderate</td>
<td>22.4 (33/147)</td>
<td>10.9 (13/119)</td>
<td>10.7 (6/56)</td>
<td>6.2 (2/32)</td>
</tr>
<tr>
<td>Heavy</td>
<td>2.1 (3/147)</td>
<td>1.7 (2/119)</td>
<td>0 (0/56)</td>
<td>0 (0/32)</td>
</tr>
<tr>
<td>Hookworms*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>98.9 (422/426)</td>
<td>99.5 (401/403)</td>
<td>99.2 (381/384)</td>
<td>99.7 (374/375)</td>
</tr>
<tr>
<td>Light</td>
<td>100 (4/4)</td>
<td>100 (2/2)</td>
<td>100 (3/3)</td>
<td>100 (1/1)</td>
</tr>
<tr>
<td>Moderate</td>
<td>0.0 (0/4)</td>
<td>0.0 (0/2)</td>
<td>0.0 (0/0)</td>
<td>0.0 (0/0)</td>
</tr>
<tr>
<td>Heavy</td>
<td>0.0 (0/4)</td>
<td>0.0 (0/2)</td>
<td>0.0 (0/0)</td>
<td>0.0 (0/0)</td>
</tr>
</tbody>
</table>

\* Light (1–4,999 epg/gram [epg]), moderate (5,000–49,999 epg), heavy (>50,000 epg).

\* Light (1–9,999 epg), moderate (10,000–9,999 epg), heavy (>10,000 epg).

\* Light (1–1999 epg), moderate (2,000–3,999 epg), heavy (>4,000 epg).
FIGURE 3. (A) *Ascaris lumbricoides* and cure rates at baseline with albendazole alone and then with combination treatment as defined by Kato–Katz. Flow diagrams showing outcomes for participants with stool samples positive for *Ascaris lumbricoides* at days 1, 20, and 90, grouped by WHO burden category and colored by outcomes after albendazole monotherapy as assessed at follow-up stool testing on day 20. On days 90 and 130, individuals received treatment as defined per stool testing results and either received albendazole 400 mg alone or in combination with ivermectin. Reduced burden is defined here as downgrade of infection intensity by at least one WHO burden category. Cure rates are noncumulative and based on the number of infected participants at the beginning of each time period. Each round of therapy resulted in a cure rate of 80% (first period), 79% (second period), and 80% (third period). Cure was attained independently of the burden level at the time of treatment. (B) Treatment outcomes for *Trichuris trichiura* infection after albendazole monotherapy and after combined therapy with albendazole and ivermectin. Flow diagrams showing outcomes for participants with stools samples positive for *Trichuris trichiura* at days 1, 20, and 90, grouped by WHO burden category and colored by outcomes after albendazole monotherapy at day 20, and after combined albendazole with ivermectin at days 90 and 130, respectively. Reduced burden is defined here as downgrade of infection intensity by at least one WHO burden category. Cure rates are noncumulative and based on the number of infected participants at the beginning of each time period. The infection status of the population under study grouped by burden of infection for *Trichuris* during three periods: 1) enrollment and day 20 after albendazole therapy, 2) days 20–90, and 3) days 90–130 after their initial deworming. The infection status of the population under study grouped by burden of infection for *Ascaris* during three periods: 1) enrollment and day 20 after albendazole therapy, 2) days 20–90, and 3) days 90–130 after their initial deworming.
infection continues to respond poorly to albendazole therapy, an observation that is not new but has not yet driven a change in STH program policy in many settings, including Peru. There is a paucity of prior published studies in Peru documenting program efficacy of the current STH program. In Iquitos, a similar treatment efficacy study was performed in 2010 among fifth-grade children (approximately 10 years of age).\textsuperscript{30} Parasite prevalence was higher in this previous study compared with the current study, particularly that of hookworm, which is likely in part due to the differing age structure of the two study populations because hookworm prevalence generally peaks later in childhood than Ascaris or Trichuris infection. Efficacy of single-dose albendazole against Ascaris infection was 99.6% (95% CI: 97.8–100), and the ERR was 99.8 (95% CI: 99.3–100), notably higher than we have documented in the present study. Similar between the two studies was a CR of only 12.8% (95% CI: 8.0–18.2%) for Trichuris infection after single-dose albendazole in the prior study and 27.1% in the current study. These studies were separated in time by 10 years and further distinguished by 6 years of the consistent and the regular application of population-level treatment of 2- to 11-year-old children in the region. Although it is possible that other factors such as undernutrition and interactions with food may play a role in these differences, both these studies were conducted in the same area during programmatic application, and we do not feel these theoretical factors contributed to the disparate findings. The observed difference points to the need for periodic monitoring of treatment efficacy as part of programmatic monitoring and evaluation of STH control as opposed to exclusively measuring treatment coverage, a common practice in the monitoring of these programs.

Monotherapy for the control of STH has advantages, primarily those of simplicity and decreased logistic burden, which are notable advantages enabling both patient compliance and mass drug administration. Combination chemotherapy has the advantage of controlling the emergence of resistance and the ability to treat all four major STH (Ascaris, Trichuris, Hookworm, and Strongyloides) more effectively. The addition of ivermectin as a second agent added to benzimidazoles (albendazole) was recommended by the Global Program to Eliminate Lymphatic Filariasis for the control of lymphatic filariasis in areas where loiasis is not coendemic; this provides important data on safety and tolerance.\textsuperscript{31} The efficacy and safety have been independently evaluated in STH treatment,\textsuperscript{32} where it has been shown to be more efficacious in controlling Trichuris infection than albendazole alone.\textsuperscript{32} The dose used by clinicians in Peru was influenced by dose-finding studies demonstrating that doses of 600 µg/kg are more effective than lower doses, particularly the standard dose of 200 mg/kg,\textsuperscript{33} and a single combined dose of each albendazole and high-dose ivermectin in addition to albendazole was associated with lower egg counts for persistent infections with Trichuris, but not for Ascaris.

The additional data on low-dose ivermectin and albendazole have been highly efficacious but only slightly more effective than low-dose ivermectin and albendazole. Oxantel would not be expected to have the additional benefits that ivermectin has of treating Strongyloides and scabies and is only produced for human use in a limited number of countries in a combined form with pyrantel pamoate.

In our study, for children who were infected with Trichuris and remained persistently positive at 20 days after treatment with albendazole received combined single-dose therapy with albendazole (400 mg) and ivermectin (600 µg/kg), the CR increased to 75%, and all heavy infections were either cured or downgraded. Despite the increased logistic complexity of an anthelmintic strategy that contains more than one agent, this alternative regimen retains the principal feature of logistic feasibility for mass drug administration—the application of complete therapy in a single dose. Note should be made of trend in decreased efficacy of dual therapy of albendazole and ivermectin in the treatment of Ascaris infection, but this difference was not statistically significant with broadly overlapping confidence intervals due to a relatively small sample size.

Between the first and third samples, the prevalence of reinfection was 18.6% for Ascaris lumbricoides, whereas between the first and third samples, the prevalence of reinfection for Trichuris trichiura was 41.2%. Between the third and fourth samples, the prevalence of reinfection was 11.8% for Ascaris lumbricoides and 7.1% for Trichuris trichiura, indicating intense transmission in this area and suggesting a need for increased treatment frequency, more efficacious anthelmintics, or combined strategies to decrease the intensity of infection in this area with concurrent interventions to improve water and sanitation infrastructure. Although single stool exams may mis-categorize individuals as being reininfected (by failure to detect a persistent low-burden infection at a single time point), we feel that the failure of multiple rounds of therapy seen in this study is of clinical and public health importance. Studies employing parasite genotyping would be required to distinguish definitively between persistent positivity with intermittent detection and reinfection.

The principal limitation of this study is that the comparison of treatments was not done after randomization, and treatment of previously treated children, who are likely to have had less intense infections may increase the apparent efficacy of second-round therapies. Randomized clinical trials would add additional strength to the evidence of the relative
efficacy of albendazole versus albendazole and high-dose ivermectin and possibly alternative combined therapies34–37 to increase the efficacy of STH control programs in the area.

CONCLUSION

The results of the study indicate that the albendazole has decreased efficacy against both Ascaris and Trichuris infection in the Peruvian Amazon. Alternative strategies that use different agents or combined therapy are needed to decrease rates of transmission and burden of STH in preschool and school-age children.

Received July 31, 2023. Accepted for publication March 1, 2024. Published online May 28, 2024.


Acknowledgments: Martin Casapia Morales provided important guidance in study design and the selection of the study population. Richard L. Guerra and Cesar Ramal Asayag provided input on treatment options and editing. Rosa Mercedes Freitas provided insights into programmatic decision-making at the national and local levels in Peru and coordinated care with the local health care system. Miguel Moncada and Lucero Romina provided tireless fieldwork, and Marvin Emilio Yalta provided valuable assistance in parasitology.

Financial support: The protocol referenced in this publication is under grant number D43TW010913, Financial support: The protocol referenced in this publication is under grant number D43TW007393 for training in emerging disease epidemiology research awarded by the Fogarty International Center of the U.S. NIH. Additional support was provided by T32AI055432 Global Biothreats Training Program to T. G. Flynn, and K43TW012298 to F. Schiaffino, and K01AI168493 to J. M. Colston. The funder was not involved in the study protocol described herein.

Author’s addresses: Greisi Curico, Hospital Regional de Loreto, Iquitos, Peru, E-mail: greisi.elena_91@gmail.com, Paul F. Garcia Bardales, Tackeshy N. Pinedo Vasquez, Wagner Shapiama, Maribel Paredes Olortegui, Asociacion Benefica PRISMA, Iquitos, Peru, E-mails: pgarcia@prisma.org.pe, tpinedo@prisma.org.pe, and mparedeso@prisma.org.pe. Francesca Schiaffino, Universidad Peruana Cayetano Heredia, Lima, Peru, E-mail: francesca.schiaffino@upch.pe, Pablo Peña Nájera, Hospital Regional de Loreto, Iquitos, Peru, E-mails: e6706413. Available at: https://www.who.int/news-room/fact-sheets/detail/sold-transmitted-helminth-infections. Accesssed September 10, 2022.


